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Essentials
• ClotChip is a novel microsensor for comprehensive assessment of ex vivo hemostasis.
• Clinical samples show high sensitivity to detecting the entire hemostatic process.
• ClotChip readout exhibits distinct information on coagulation factor and platelet abnormalities.
• ClotChip has potential as a point-of-care platform for comprehensive hemostatic analysis.
Summary. Background: Rapid point-of-care (POC) assessment of hemostasis is clinically important in patients with a variety of coagulation factor and platelet defects who have bleeding disorders. Objective: To evaluate a novel dielectric microsensor, termed ClotChip, which is based on the electrical technique of dielectric spectroscopy for rapid, comprehensive assessment of whole blood coagulation. Methods: The ClotChip is a three-dimensional, parallel-plate, capacitive sensor integrated into a single-use microfluidic channel with miniscule sample volume (< 10 lL). The ClotChip readout is defined as the temporal variation in the real part of dielectric permittivity of whole blood at 1 MHz. Results: The ClotChip readout exhibits two distinct parameters, namely, the time to reach a permittivity peak (T peak ) and the maximum change in permittivity after the peak (De r,max ), which are, respectively, sensitive towards detecting non-cellular (i.e. coagulation factor) and cellular (i.e. platelet) abnormalities in the hemostatic process. We evaluated the performance of ClotChip using clinical blood samples from 15 healthy volunteers and 12 patients suffering from coagulation defects. The ClotChip T peak parameter exhibited superior sensitivity at distinguishing coagulation disorders as compared with conventional screening coagulation tests. Moreover, the ClotChip De r,max parameter detected platelet function inhibition induced by aspirin and exhibited strong positive correlation with light transmission aggregometry. Conclusions: This study demonstrates that ClotChip assesses multiple aspects of the hemostatic process in whole blood on a single disposable cartridge, highlighting its potential as a POC platform for rapid, comprehensive hemostatic analysis.
Introduction
Early identification of hemostatic dysregulation and bleeding risk is important in the management of patients who are critically ill, severely injured or on antiplatelet/ anticoagulation therapies [1] . Conventional laboratorybased coagulation tests are time consuming, labor intensive, and are not reliable indicators of hemostatic risk. Extant handheld point-of-care (POC) devices have uses that are limited to specific patient populations (e.g. CoaguChek for warfarin use), have low thromboplastin and partial thromboplastin reagent sensitivity (e.g. i-STAT device), resulting in only suboptimal assessment of the coagulation process, and do not provide concurrent information on platelet function. Although thromboelastography (TEG) and rotational thromboelastometry (ROTEM) allow for the analysis of several aspects of clot formation and strength, representing a global measure of the hemostatic process, these viscoelastic tests rely on sensitive mechanical components that are expensive and difficult to miniaturize. Hence, there is an unmet clinical need for a low-cost, easy-to-use and portable platform for comprehensive POC assessment of hemostasis outside of a central laboratory.
To address this need, we adapted the method of dielectric spectroscopy (DS), an electrical, label-free and non-invasive technique, to monitor the hemostatic process ex vivo in a disposable microfluidic sensor. DS is the quantitative measurement of permittivity vs. frequency and is a well-established method to extract information on the molecular and cellular components of biological tissues [2, 3] . The main response of blood DS measurements in the MHz-frequency range arises from the interfacial polarization of cellular components [4, 5] . DS measurements within the resulting dispersion region are used to gain information on the physical properties of blood [6, 7] . In particular, DS measurements on blood in the MHz-frequency range are sensitive to aggregation of erythrocytes into a fibrin clot and subsequent erythrocyte deformation as a result of contractile forces from activated platelets [8] [9] [10] that characteristically occur during clot formation [11] . DS that assesses the blood coagulation process is termed dielectric coagulometry. We have developed a novel dielectric microsensor, termed ClotChip, which performs dielectric coagulometry on a miniscule volume (<10 lL) of whole blood. Presently, we show that ClotChip readouts are sensitive to several aspects of the hemostatic process, including thrombin formation and platelet activation. These features allow for comprehensive assessment of the hemostatic process ex vivo in a potentially portable platform, which is ideal for a POC device.
Methods

ClotChip fabrication and measurements
The ClotChip featured a parallel-plate capacitive sensor to extract the dielectric permittivity of whole blood within a microfluidic channel [12] . Two planar sensing electrodes were separated from a floating electrode through a microfluidic channel to form a three-dimensional capacitive sensing area. With a blood sample passing through this area, the impedance of the sensor would change based upon its dielectric permittivity. ClotChip was fabricated using biocompatible, chemically inert, polymethyl methacrylate (PMMA) plastic substrate and cap (Fig. 1A) [13, 14] . The sensor fabrication and assembly process was based on a low-cost (< $1 material cost per chip) batch-fabrication method of screen-printing gold electrodes onto a 1.5 mmthick PMMA plastic substrate and cap. A double-sided adhesive (DSA) film with thickness of 250 lm was laser micromachined to form the walls of a microfluidic channel with dimensions of 12 mm 9 3 mm, and then the ClotChip was assembled by attaching the PMMA cap to the PMMA substrate using the DSA film (Fig. 1B) . The fabricated sensor (Fig. 1C) had a size of 26 mm 9 9 mm 9 3 mm and a total sample volume of 9 lL. The sensor was loaded with whole blood using a micropipette, placed into a thermostatic chamber set at 37°C, and characterized with an impedance analyzer (Agilent 4294A; Santa Rosa, CA, USA) over a frequency range of 10 kHz to 100 MHz to capture the dispersion region associated with red blood cell (RBC) membrane polarization (Fig. 1D ). Measurements were performed at 10-s intervals over a total measurement time of 30 min. The electrical properties of whole blood varied during coagulation, and a measurement frequency of 1 MHz was chosen to maximize the sensitivity to clot formation dynamics, including RBC aggregation and deformation. Therefore, the ClotChip readout was taken as the temporal variation in the real part of blood dielectric permittivity at 1 MHz (Fig. 1E ).
Study design
All healthy volunteers and patients who enrolled in this study provided informed consent. The collection and use of blood samples from subjects were approved by the Institutional Review Board of University Hospitals Cleveland Medical Center. Blood samples were drawn by venipuncture into collection tubes containing 3.2% sodium citrate anticoagulant (ratio of blood to anticoagulant = 9 : 1), and were used for both ClotChip measurements and conventional coagulation assays. Healthy volunteers were accrued only if they were off medications and without diagnosis of an illness in the past 4 weeks. Twelve patients with coagulation defects (Table 1) were accrued from a hematology clinic and had been previously characterized by comprehensive medical history, screening coagulation tests and specialized coagulation studies.
ClotChip measurements were performed in a research laboratory by a trained doctoral student within 2 h from the time of blood collection. Prior to measurements and to initiate coagulation, 25.6 lL of 250 mM CaCl 2 was pipetted into 300 lL of citrated blood sample that was pre-warmed to 37°C in a heating chamber, and 10 lL of the mixture was immediately injected into the ClotChip.
Additional ClotChip measurements were performed with whole blood obtained by fingerstick using a 23-gauge lancet and wiping away the first drop of blood. Another two to three drops of blood were collected in a polypropylene tube, after which 10 lL of whole blood was immediately injected into the ClotChip using a micropipette. Duplicate measurements were performed within 1 min following the fingerstick procedure.
Calibration of the measurement set-up was performed daily to implement quality control and ensure accurate electrical measurement of the blood sample. This step was performed using a custom printed circuit board in the form of the ClotChip sensor that contained an equivalent circuit model of whole blood [12] . Additional quality control was implemented by testing a control sample from a pool of known healthy volunteer donors on each day that patient samples were examined.
Platelet inhibition studies
Platelet inhibition studies were performed ex vivo with blood samples from 10 healthy volunteers. Samples for ClotChip measurements were prepared by mixing whole blood with 120 mM aspirin in DMSO (final aspirin concentration of 0 to 2 mM), followed by incubation for 30 min at room temperature. Light transmission aggregometry (LTA) experiments were performed using platelet-rich plasma (PRP) within 3 h of blood collection. PRP was diluted to 2.2 9 10 8 platelets per mL, then treated with aspirin (1 or 2 mM) for 30 min at room temperature. Aggregation was initiated with ADP (5 or 10 lM), arachidonic acid (0.5 mM) or SFLLRN (PAR1 agonist peptide, 10 lM). Aggregation was measured using a lumi-aggregometer (Model 700, Chrono-log Corp). The sample was stirred constantly at 1200 rpm at 37°C. . Spring-loaded electrical contact pins were used to provide a plug-and-play-type connection and enable rapid user replacement of the disposable sensor. (C) Photograph of prototype ClotChip sensor with sample volume of 9 lL. (D) Sensor measurements showing the real part of dielectric permittivity of human whole blood and blood plasma versus frequency. The permittivity of whole blood versus frequency exhibited a dispersion region (~200 kHz to 50 MHz) due to red blood cell (RBC) membrane interfacial polarization (as evident by the absence of this region in plasma measurement). (E) Example of the ClotChip readout for a human whole blood sample (collected in 3.2% sodium citrate anticoagulant) without (black) and with (blue) coagulation initiated by the addition of CaCl 2 . The ClotChip readout was taken as the time course of variation in the real part of blood dielectric permittivity at 1 MHz. A peak in permittivity was observed for the CaCl 2 -treated sample, whereas no such peak was observed for the citrated sample, indicating that the permittivity of whole blood at 1 MHz was sensitive to the coagulation process. [Color figure can be viewed at wileyonlinelibrary.com]
Statistical analysis
Data obtained in this study are reported as mean AE standard error of the mean (SEM). The Wilcox matched-pairs signed test was used for comparing outcomes between two paired groups and the Mann-Whitney U-test otherwise. All statistical comparisons were two-tailed. The statistical significance threshold was set at the 95% confidence level for all tests (P < 0.05). Statistical data analysis was performed using Minitab 17 and GraphPad Prism software suites (GraphPad Software, San Diego, CA, USA).
Results and discussion
ClotChip measurements from 15 healthy volunteers who had normal activated partial thromboplastin time (APTT) and prothrombin time (PT) values are shown in Fig. 2(A) . A characteristic rise to a permittivity peak was observed within 240-505 s (T peak ). Based on our previous studies, the T peak parameter was taken to be indicative of coagulation time [14, 15] . ClotChip measurements then were performed with 12 patient samples obtained from individuals with well-characterized bleeding disorders. Compared with the normal curve, samples from patients with coagulopathy exhibited abnormal curves (Fig. 2B ) with a significantly prolonged T peak range of 675-3550 s (P < 0.0001; Fig. 2C ). The precision of T peak was evaluated by calculating a percentage coefficient of variance (CV) as the ratio of the within-subject standard deviation and the overall mean 9 100 [16] . We used duplicate measurements from the 15 normal samples and 12 patient samples to establish a CV for 'normal' and 'high' ranges of T peak , respectively. The normal samples exhibited a mean T peak of 371 s and CV of 7.6%. The patient samples exhibited a mean T peak of 1267 s and CV of 8.6%. The ClotChip CV values are similar to the reported precision (~6%) of a commercially available POC blood coagulation test [17] .
Conventional coagulation tests (APTT and PT) were also performed for each sample. It should be noted that the most prolonged APTT coagulation time was observed in the sample with factor XII deficiency, which also had the most prolonged T peak . We also observed prolonged APTT coagulation times as well as prolonged T peak values in all moderate and severe hemophilia samples, accurately capturing this type of coagulopathy. However, for mild hemophilia A and von Willebrand type 2B cases, both the APTT and PT were normal. These patients were diagnosed with specialized coagulation assays following referral to our hematology clinic for work-up of clinical bleeding. In both cases, the ClotChip readout did show a prolonged T peak , indicating its superior sensitivity. Taken together, the data confirmed that ClotChip could capture defects in multiple aspects of the hemostatic pathway, with improved sensitivity as compared with standard screening coagulation tests.
We then investigated the effect of aspirin-induced inhibition of platelet activity on the ClotChip readout. Samples were treated with various concentrations of aspirin ex vivo. LTA studies were run on each sample, and we observed that with arachidonic acid-induced platelet aggregation, the percentage aggregation was reduced from > 70% for baseline measurements to < 5% for all aspirintreated samples, confirming platelet inhibition in response to aspirin treatment. We found that aspirin treatment did not significantly change T peak (Fig. 2D) , as we had previously observed with coagulation factor defects. However, aspirin dose-dependently decreased the De r,max parameter, defined as one minus the ratio of final permittivity (i.e. FVIII:C, factor VIII coagulant activity (%); FIX:C, factor IX coagulant activity (%); FXII:C, factor XII coagulant activity (%); VWF, von Willebrand factor; RCA, ristocetin cofactor assay. Patients with classic hemostatic defects were accrued from a specialty hematology clinic and agreed to participate in this study. ClotChip measurements along with relevant coagulation tests were performed.
permittivity at 30 min) and peak permittivity (i.e. permittivity at T peak ; Fig. 2E ). Compared with untreated samples, a significant decrease in De r,max was observed for samples that were treated with 1 mM aspirin (n = 10, P < 0.0001) or 2 mM aspirin (n = 10, P < 0.0001; Fig. 2F ). The ClotChip De r,max parameter exhibited the strongest correlation (r = 0.81, P < 0.001, n = 30) with the percentage aggregation parameter of LTA with 5 lM ADP (Fig. 2G) . These data showed that the ClotChip De r,max parameter was sensitive to platelet activity. Finally, we investigated the effect of pre-analytical conditions on the ClotChip readout. To test sample stability, we performed repeated measurements at different timepoints for blood samples from six healthy volunteers. Samples were stored at room temperature and duplicate ClotChip measurements were performed at 30 min, 1.5, 2.5, 3.5 and 4.5 h after blood collection. The studies showed a downward trend in mean T peak as storage time increased (Fig. 3A) . The first of these results (performed 30 min after blood collection) represented the reference T peak for each sample, and the stability at different timepoints was analyzed via comparison with this first T peak value [18] . A significant difference was found for groups at 3.5 h (P < 0.005) and 4.5 h (P < 0.005) compared with the group at 30 min. No significant difference was found for groups at 2.5 h and 1.5 h compared with 30 min. These results demonstrate that ClotChip readout exhibits repeatable characteristics for citrated whole blood tested within 2.5 h from blood draw.
We then investigated the feasibility of using whole blood obtained from a fingerstick blood-collection method. Five healthy volunteers were recruited to donate blood by fingerstick and venipuncture techniques. Figure 3(B) shows nearly identical ClotChip readout for whole blood obtained by fingerstick and re-calcified whole blood obtained from venipuncture. Although we did observe a decrease in T peak values for fingerstick samples (range: 260-360 s) compared with re-calcified venipuncture samples (range: 320-440 s) as shown in Fig. 3(C) , the T peak values for all fingerstick samples fell within the range of all 15 healthy volunteers, as reported above ( Fig. 2A,C) . This study demonstrates the potential of ClotChip to accurately perform with whole blood obtained from a fingerstick.
In conclusion, we show that the ClotChip readout of dielectric permittivity of whole blood at 1 MHz is sensitive to a wide range of hemostatic defects. Specifically, two distinct parameters of the ClotChip readout, T peak and De r,max , provide independent information on hemostatic defects arising from non-cellular (i.e. coagulation factor) and cellular (i.e. platelet) components, respectively, thereby allowing a discriminatory assessment of the comprehensive blood coagulation process. Although early work on dielectric coagulometry revealed sensitivity to both clotting time and platelet activity [19] [20] [21] , this technique was restricted to laboratory-based benchtop equipment and > 100 lL-volume samples [22] [23] [24] [25] . The ClotChip sensor used in this study features a simple fabrication process and enables dielectric coagulometry to be performed with < 10 lL of blood sample volume in a disposable sensor. Furthermore, the electrical technique of dielectric coagulometry does not require bulky optical or mechanical components and is thus ideal for a POC platform. Although a small sample size of patients with known coagulation defects was employed in this proofof-concept investigation, these initial studies pave the way for the development of a portable platform that allows for clinical testing to be performed at the POC. In future investigations we plan to expand the sample size, use the device to screen patients for disease, assess blood coagulation testing phenomena such as lupus anticoagulants, and determine the correlation of test results with bleeding. We believe these studies are needed before translation to clinical practice. Nonetheless, our present work establishes that ClotChip has potential as a portable platform for rapid, comprehensive assessment of hemostasis at the POC using < 10 lL of whole blood. 
